A bloodâ based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial

IntroductionMultinutrient approaches may produce more robust effects on brain health through interactive qualities. We hypothesized that a bloodâ based nutritional risk index (NRI) including three biomarkers of diet quality can explain cognitive trajectories in the multidomain Alzheimer prevention trial (MAPT) over 3â years.MethodsThe NRI included erythrocyte nâ 3 polyunsaturated fatty acids (nâ 3 PUFA 22:6nâ 3 and 20:5nâ 3), serum 25â hydroxyvitamin D, and plasma homocysteine. The NRI scores reflect the number of nutritional risk factors (0â 3). The primary outcome in MAPT was a cognitive composite Z score within each participant that was fit with linear mixedâ effects models.ResultsEighty percent had at lease one nutritional risk factor for cognitive decline (NRI â ¥1: 573 of 712). Participants presenting without nutritional risk factors (NRI=0) exhibited cognitive enhancement (β = 0.03 standard units [SU]/y), whereas each NRI point increase corresponded to an incremental acceleration in rates of cognitive decline (NRIâ 1: β = â 0.04 SU/y, P = .03; NRIâ 2: β = â 0.08 SU/y, P < .0001; and NRIâ 3: β = â 0.11 SU/y, P = .0008).DiscussionIdentifying and addressing these wellâ established nutritional risk factors may reduce ageâ related cognitive decline in older adults; an observation that warrants further study.Highlightsâ ¢Multiâ nutrient approaches may produce more robust effects through interactive propertiesâ ¢Nutritional risk index can objectively quantify nutritionâ related cognitive changesâ ¢Optimum nutritional status associated with cognitive enhancement over 3â yearsâ ¢Suboptimum nutritional status associated with cognitive decline over 3â yearsâ ¢Optimizing this nutritional risk index may promote cognitive health in older adultsPeer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152935/1/trc2jtrci201911004.pd

Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease

Recent genome-wide association studies of Alzheimer's disease (AD) have identified variants in BIN1, CLU, CR1 and PICALM that show replicable association with risk for disease. We have thoroughly sampled common variation in these genes, genotyping 355 variants in over 600 individuals for whom measurements of two AD biomarkers, cerebrospinal fluid (CSF) 42 amino acid amyloid beta fragments (Aβ42) and tau phosphorylated at threonine 181 (ptau181), have been obtained. Association analyses were performed to determine whether variants in BIN1, CLU, CR1 or PICALM are associated with changes in the CSF levels of these biomarkers. Despite adequate power to detect effects as small as a 1.05 fold difference, we have failed to detect evidence for association between SNPs in these genes and CSF Aβ42 or ptau181 levels in our sample. Our results suggest that these variants do not affect risk via a mechanism that results in a strong additive effect on CSF levels of Aβ42 or ptau181

Facteurs pronostiques de déclin fonctionnel chez des patients atteints de maladie d'Alzheimer (cohorte REAL.FR)

L'objectif de cette étude est de déterminer des facteurs pronostiques de déclin fonctionnel chez des patients atteints de MA vivant à domicile. Méthode : Six cent quatre vingt six patients de la cohorte REAL.FR ont été suivis pendant 4 ans et ont bénéficié d'une évaluation semestrielle. Résultats : Un MMSE compris entre 15 et 10 (3.95 -0.42/6 mois p<0.01), une perte de points au score ADL (5.31 -0.31/6 mois p<0.01) et un test d'appui unipodal anormal (3.91 -0.32/6 mois p<0.01), MNA-SF inférieur à 12 (4.7 -0.29/6 mois p=0.03) sont des facteurs pronostiques péjoratifs de déclin fonctionnel. Notre étude exploratoire a montré qu'il existe plusieurs facteurs pronostiques a priori modifiables de déclin fonctionnel tels que le déclin cognitif, les difficultés dans les actes de la vie quotidienne, le déclin des performances physiques et le statut nutritionnel qui peuvent être la cible d'interventions spécifiques visant à ralentir l'aggravation de la dépendance.TOULOUSE3-BU Santé-Centrale (315552105) / SudocSudocFranceF

Score de risque de déclin fonctionnel pour les patients atteints de maladie d'Alzheimer (application en médecine générale)

TOULOUSE3-BU Santé-Centrale (315552105) / SudocSudocFranceF

Facteurs associés à la prescription de calcium-vitamine D chez les sujets agés en institution

TOULOUSE3-BU Santé-Centrale (315552105) / SudocSudocFranceF

Retraction of: Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia

International audienc

Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia

Population aging is rapidly accelerating worldwide; however, longer life expectancy is not the only public health goal. Indeed, extended lifetime involves maintaining function and the capacity of living independently. Sarcopenia and physical frailty are both highly relevant entities with regards to functionality and autonomy of older adults. The concepts and definitions of frailty and sarcopenia have largely been revised over the years. Sarcopenia is an age-related progressive and generalized loss of skeletal muscle mass and strength. On the other hand, frailty is a state of increased vulnerability to stressors, responsible for exposing the older person to enhanced risk of adverse outcomes. Physical frailty and sarcopenia substantially overlap and several adverse outcomes of frailty are likely mediated by sarcopenia. Indeed, the concepts of sarcopenia and physical frailty can be perceived as related to the same target organ (i.e., skeletal muscle) and it may be possible to combine them into a unique definition. The biological background of such a close relationship needs to be explored and clarified as it can potentially provide novel and pivotal insights for the assessment and treatment of these conditions in old age. The aim of this paper is to indicate and discuss possible biological markers to be considered in the framing of physical frailty and sarcopenia

RETRACTED: Association Between Frailty and Cognitive Impairment: Cross-Sectional Data From Toulouse Frailty Day Hospital

International audienc

Intérêt d’une supplémentation nutritionnelle par CNO chez les résidents d’EHPAD en France. Etude d’intervention chez 108 résidents

National audienc